Keros Capital Announces New Client Overview: MabCure Inc. (OTCBB: MBCI)
(EMAILWIRE.COM, November 12, 2009 ) New York, NY - MabCure has invented a brilliant new way to spot and successfully “mark” cancer cells at their earliest stage, so that they literally stand out, and can then be eliminated. The opportunity is so immense, some analysts predict the market for this...more
Keros Capital Client MABCURE Signs Research Agreement With AZ Sint Lucas Hospital, Brugge, Belgium, to Conduct Preclinical Research on its Monoclonal Antibodies (Mabs) against Different Cancers
(EMAILWIRE.COM, November 12, 2009 ) New York, NY - MabCure N.V., a subsidiary of MabCure Inc. (OTC BB: MBCI), a biotech company that has developed a series of highly specific monoclonal antibodies (Mabs) to combat various types of cancers, has signed a research agreement with AZ Sint Lucas Hospital,...more
MabCure Inc. (OTCBB: MBCI) Working on Therapies For Three Cancers
(EMAILWIRE.COM, November 04, 2009 ) New York, NY - Keros Client Developing Antibodies For Three Cancers Ovarian Cancer is Almost Always Detected When It’s Too Late - Forbes magazine Calls This, “Scandalous” and They’re Right. Last year 22,430 new cases were diagnosed and 15,280 women died...more
MabCure Inc. (OTCBB: MBCI) Becoming a Major Player in a Multi-Billion Dollar Market
(EMAILWIRE.COM, November 04, 2009 ) New York, NY - Just two years ago, the therapeutic antibodies market enjoyed industry-wide sales of $7.3 billion. This market is expected to grow by 30% annually and reach $22 billion by 2010. Cancer dominates this market because the rewards of success dwarf...more
MabCure Inc. (OTCBB: MBCI) Unknown Enterprise Revolutionizing the Attack on Cancer
(EMAILWIRE.COM, November 04, 2009 ) New York, NY - MabCure did a pilot study looking at 13 patients with ovarian cancer—half of which went through chemotherapy. They examined the blood of these patients with the antibodies they discovered. The objective was to see if their antibodies could successfully...more
Company Overview: MabCure Inc. (OTCBB: MBCI)
(EMAILWIRE.COM, November 04, 2009 ) New York, NY - MabCure has invented a brilliant new way to spot and successfully “mark” cancer cells at their earliest stage, so that they literally stand out, and can then be eliminated. The opportunity is so immense, some analysts predict the market for this...more
Griffin Securities Has Announced Investment Opinion on Cancer Targeting Stem Cells
(EMAILWIRE.COM, November 03, 2009 ) November 3, 2009, New York, NY – Keros Capital announces that Griffin Securities (“Griffin”), a research-driven investment banking firm, has released an industry report on the subject of targeting cancer stem cells (CSCs). The stem cell hypothesis offers a rational...more
MabCure Inc. Spotlighted in Two Published Reports on Cancer Stem Cell Research
(EMAILWIRE.COM, November 03, 2009 ) November 3, 2009, New York, NY - Keros Client, MabCure Inc. (OTCBB: MBCI), a biotech company that has developed a series of highly specific monoclonal antibodies (Mabs) to combat various types of cancers, is highlighted in the October issue of GEN (Genetic Engineering...more
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International
Equityallianceir.com
Your text Ads & PR
Text Ads plus unlimited press releases, One release featured/Day for only $575 per month.
Read more on Text Ads & PR
Your text Ads Here!
Text Ads are only $289 per month. Ads are placed same day.
More on Text Ads Advertising
Press Release
Resources
Benefits of Online Press Release Distribution Service
Press Releases
Press Release Examples
Press Release Format
Press Release Free
Press Release Service Comparison
Press Release Writing
Press release Writing Tips